These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1494798)

  • 1. [Critical analysis of drug interactions with cyclosporine. Evaluation of interactions with cyclosporine].
    Billaud EM; Ropers J; Fortineau N; Kreft-Jais C; Babany G
    Therapie; 1992; 47(4):335-42. PubMed ID: 1494798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic follow-up of cyclosporine: specific problems in kidney, liver, bone marrow grafts and in the treatment of autoimmune diseases].
    Garraffo R
    Therapie; 1992; 47(4):327-34. PubMed ID: 1494797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of drug interactions with cyclosporine.
    Lake KD
    Pharmacotherapy; 1991; 11(5):110S-118S. PubMed ID: 1745616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
    Halacová M; Jedlicková B; Průsa R
    Ceska Slov Farm; 2003 Nov; 52(6):267-71. PubMed ID: 14661365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate sodium increases cyclosporine blood levels in renal transplant recipients.
    Pourfarziani V; Taheri S
    Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):991-4. PubMed ID: 19861858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimizing cyclosporine concentration variability to optimize transplant outcome.
    Canafax DM
    Clin Transplant; 1995 Feb; 9(1):1-13. PubMed ID: 7742576
    [No Abstract]   [Full Text] [Related]  

  • 7. [Twenty-five years of cyclosporin use in transplantation medicine].
    Hesselink DA; van Hagen PM; Balk AH; van Hal PT; Weimar W; van Gelder T
    Ned Tijdschr Geneeskd; 2003 May; 147(20):959-64. PubMed ID: 12784529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine monitoring in pediatric allograft recipients--time for a change!
    Hoyer PF
    Pediatr Transplant; 2004 Apr; 8(2):101-3. PubMed ID: 15049787
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.
    Vogel M; Voigt E; Michaelis HC; Sudhop T; Wolff M; Türler A; Sauerbruch T; Rockstroh JK; Spengler U
    Liver Transpl; 2004 Jul; 10(7):939-44. PubMed ID: 15237382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiodarone-cyclosporine interaction in a heart transplant patient.
    Nicolau DP; Uber WE; Crumbley AJ; Strange C
    J Heart Lung Transplant; 1992; 11(3 Pt 1):564-8. PubMed ID: 1610865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.
    Serkova N; Hausen B; Berry GJ; Jacobsen W; Benet LZ; Morris RE; Christians U
    J Pharmacol Exp Ther; 2000 Jul; 294(1):323-32. PubMed ID: 10871329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of cyclosporine for liver transplantation.
    Lilly LB; Grant D
    Transplant Proc; 2004 Mar; 36(2 Suppl):267S-270S. PubMed ID: 15041351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indications for therapeutic activity of cyclosporine].
    Mourani C; Mallat S; Hachem C
    J Med Liban; 2003; 51(2):80-91. PubMed ID: 15298162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic monitoring and outcomes of cyclosporine.
    Pollard SG
    Transplant Proc; 2004 Mar; 36(2 Suppl):404S-407S. PubMed ID: 15041375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of postdose cyclosporine monitoring in living renal transplant recipients.
    Thomas R; Minz M; Singh B; Heer M; Kashyap R
    Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of cyclosporine: 20 years of progress.
    Kahan BD
    Transplant Proc; 2004 Mar; 36(2 Suppl):378S-391S. PubMed ID: 15041372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin and ketoconazole, drug interaction or therapeutic association?
    Albengres E; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1992 Dec; 30(12):555-70. PubMed ID: 1473871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.